Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.

ABSTRACT:

Background

Metastatic castration-resistant prostate cancer (mCRPC) is the lethal form of the disease. Several recent studies have identified genomic alterations in mCRPC, but the clinical implications of these genomic alterations have not been fully elucidated.

Objective

To use whole-genome sequencing (WGS) to assess the association between key driver gene alterations and overall survival (OS), and to use whole-transcriptome RNA sequencing to identify genomic drivers of enzalutamide resistance.

Design, setting, and participants

We performed survival analyses and gene set enrichment analysis (GSEA) on WGS and RNA sequencing results for a cohort of 101 mCRPC patients.

Outcome measurements and statistical analysis

OS was the clinical endpoint for all univariate an

SUBMITTER: Chen WS 

PROVIDER: S-EPMC6764911 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature